BHPI is primarily utilized in the field of medicinal chemistry and drug development, particularly in the study of hormone-dependent cancers. It functions as a selective estrogen receptor degrader (SERD), targeting estrogen receptors in breast cancer cells. By degrading these receptors, BHPI effectively inhibits the growth and proliferation of cancer cells that rely on estrogen for their development. This makes it a promising candidate for the treatment of estrogen receptor-positive (ER+) breast cancer, especially in cases where traditional therapies like tamoxifen have shown resistance. Additionally, research is ongoing to explore its potential in other hormone-related conditions and cancers.